Translarna™ (ataluren) is the First Therapy Approved in Brazil for DMD

– Ambulatory Duchenne patients who are five years and older with a nonsense mutation can now access a treatment that targets the underlying cause of DMD –

 

PTC Therapeutics, Inc. today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the treatment of ambulatory children five years and older with Duchenne muscular dystrophy caused by a nonsense mutation. Patients now can have access to a treatment that targets the underlying cause.

 

Eric Pauwels, Senior Vice President and General Manager of the Americas of PTC Therapeutics, Inc.– “The regulatory approval from the Brazilian authorities will accelerate access to Translarna for the many patients who have been waiting for treatment. We are committed to working quickly to make Translarna available to all patients in Brazil who may benefit.”

 

Alexandra Prufer, Associate Professor of Pediatric Neurology, Department of Pediatrics, Medical School, The Federal University of Rio de Janeiro. – “Muscle damage in Duchenne starts very young, so early diagnosis and treatment is critical to maintain muscle function and delay disease progression. Treatment measures should be started once children are diagnosed when there is the most amount of muscle to effect.”

 

About Translarna 


Ataluren, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna, tradename ataluren, is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged two years and older. Ataluren is an investigational new drug in the United States.

CLINICAL TRIAL OF ATALUREN IN CANADA

PORTRAIT OF DUCHENNE – ATALUREN: A PROMISING TREATMENT FOR DMD

About PTC Therapeutics, Inc.


PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

Pioneers in DMD therapy

News provided by PTC Therapeutics, Inc.  Apr 29, 2019, 09:18 ET

Press Release > Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy

1 reply
  1. Falah Brindar salih
    Falah Brindar salih says:

    I have a child diagnosed with Muscular dystrophy he is now 9 years old, how can I get the treatment for him, I am leaving in Iraq.
    Thanks

    Reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.